ProCE Banner Activity

Histology-Agnostic Therapies: Clinical Pearls for Practice

PDF

Download this resource covering the latest on histology-agnostic therapies including approved indications and recommendations for biomarker testing to identify eligible patients.

Released: May 31, 2023

Share

Faculty

Nagla Abdel Karim

Nagla Abdel Karim, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
University of Virginia
Director of Early Therapeutics Program/Phase I Program
Inova Schar Cancer Institute
Fairfax, Virginia

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Aadi Bioscience, Bayer HealthCare Pharmaceuticals Inc., and Lilly.

Aadi Bioscience

Bayer HealthCare Pharmaceuticals Inc.

Lilly

Faculty Disclosure

Primary Author

Nagla Abdel Karim, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
University of Virginia
Director of Early Therapeutics Program/Phase I Program
Inova Schar Cancer Institute
Fairfax, Virginia

Nagla Abdel Karim, MD, PhD: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, G1 Therapeutics, Jazz, Pfizer, Regeneron, Sanofi; researcher: Bristol-Myers Squibb, Exelixis, Pfizer.